The vulvar immunohistochemical panel (VIP) project: molecular profiles of vulvar Paget's disease.
Biostatistics
Gynecological cancers
Immunohistochemistry
Molecular targets
Vulvar cancer
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
25
06
2019
accepted:
05
07
2019
pubmed:
13
7
2019
medline:
29
8
2019
entrez:
13
7
2019
Statut:
ppublish
Résumé
To investigate the expression of biological markers in primary vulvar Paget's disease (VPD). Forty-one patients referred to a single major Center for Gynecologic Oncology from January 2008 to June 2018 were enrolled retrospectively: 30 non-invasive-VPD and 11 invasive-VPD. A total number of 60 samples, from all the 41 vulvar sites (VS), 8 metastatic lymph node sites (MLS) and 11 successive recurrent disease in vulvar site (RVS), were tested for an immunohistochemical panel, including the following markers: PD-L1, CD3, MSH2, MSH6, MLH1, PMS2, HER2/neu, EGFR, p16, p53, Ki67, ER, PR, AR, VEGF and CD31. We found a positive PD-L1 in 10% of non-invasive-VPD and 27% of invasive-VPD (18% VS; 38% MLS). ER and AR were expressed respectively in more than 70% and 75% of all specimens. HER2/neu amplification was found in 21% of non-invasive-VPD and 45% of invasive-VPD (40% VS; 38% MLS). A machine learning cluster analysis identified three groups among non- invasive-VPD: cluster-1 with higher median ER expression (40%); cluster-3 with more frequent HER2/neu overexpression (46%). Among invasive-VPD, two clusters were found: the second with more frequent HER2/neu overexpression (67% vs. 0%) and nodal metastases (100% vs. 25%). Repeating the IHC panel on the correspondent MLS and RVS, it significantly changed, respectively, in 50% and 27%. This study reveals the expression of PDL-1 and ER and confirms the expression of HER2/AR in VPD; new bases are provided to design multicenter clinical trials on personalized target therapies.
Identifiants
pubmed: 31297606
doi: 10.1007/s00432-019-02975-3
pii: 10.1007/s00432-019-02975-3
doi:
Substances chimiques
Neoplasm Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2211-2225Références
Alessandrini L, Clemente N, Perin T, Giorda G, Canzonieri V, Sopracordevole F (2018) Extramammary Paget disease of the vulva: immunohistochemical analysis of neoangiogenesis and epithelial-mesenchymal transition markers expression. Diagn Pathol 13(1):2
doi: 10.1186/s13000-017-0680-x
pubmed: 29368628
pmcid: 6389142
Al-Obaidy KI, Kao C-S, Idrees MT (2018) P16 expression in extramammary Paget’s disease of the vulva and scrotum is not human papillomavirus related. Int J Surg Pathol 1:1066896918775513
Azmahani A, Nakamura Y, Ozawa Y, McNamara KM, Fujimura T, Haga T et al (2015) Androgen receptor, androgen-producing enzymes and their transcription factors in extramammary Paget disease. Hum Pathol 46(11):1662–1669
doi: 10.1016/j.humpath.2015.07.007
pubmed: 26359540
Chen S-Y, Takeuchi S, Moroi Y, Hayashida S, Kido M, Uchi H et al (2008) Concordant over-expression of transcription factor Sp1 and vascular endothelial growth factor in extramammary Paget’s disease. Int J Dermatol 47(6):562–566
doi: 10.1111/j.1365-4632.2008.03643.x
pubmed: 18477144
Diaz de Leon E, Carcangiu ML, Prieto VG, McCue PA, Burchette JL, To G et al (2000) Extramammary Paget disease is characterized by the consistent lack of estrogen and progesterone receptors but frequently expresses androgen receptor. Am J Clin Pathol 113(4):572–575
doi: 10.1309/P756-XXCB-TV71-U4XV
pubmed: 10761460
Edey KA, Allan E, Murdoch JB, Cooper S, Bryant A (2013) Interventions for the treatment of Paget’s disease of the vulva. Cochrane Database Syst Rev 26(10):CD009245
Ellis PE, Fong LFWT, Rolfe KJ, Crow JC, Reid WMN, Davidson T et al (2002a) The role of p53 and Ki67 in Paget’s disease of the vulva and the breast. Gynecol Oncol 86(2):150–156
doi: 10.1006/gyno.2002.6629
pubmed: 12144821
Ellis PE, Wong Te Fong LF, Rolfe KJ, Crow JC, Reid WMN, Davidson T et al (2002b) The role of vascular endothelial growth factor-A (VEGF-A) and platelet-derived endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/TP) in Paget’s disease of the vulva and breast. Anticancer Re 22(2A):857–861
Ellis PE, MacLean AB, Wong Te Fong LF, Crow JC, Perrett CW (2012) Angiogenesis in Paget’s disease of the Vulva and the Breast: correlation with microvessel density. J Oncol [Internet] Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3321467/
Fujimoto A, Takata M, Hatta N, Takehara K (2000) Expression of structurally unaltered androgen receptor in extramammary Paget’s disease. Lab Investig J Tech Methods Pathol 80(9):1465–1471
doi: 10.1038/labinvest.3780153
Garganese G, Collarino A, Fragomeni SM, Rufini V, Perotti G, Gentileschi S et al (2017) Groin sentinel node biopsy and 18F-FDG PET/CT-supported preoperative lymph node assessment in cN0 patients with vulvar cancer currently unfit for minimally invasive inguinal surgery: the GroSNaPET study. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 43(9):1776–1783
Gentileschi S, Servillo M, Garganese G, Fragomeni S, De Bonis F, Scambia G et al (2016) Surgical therapy of vulvar cancer: how to choose the correct reconstruction? J Gynecol Oncol. 27(6):e60
doi: 10.3802/jgo.2016.27.e60
pubmed: 27550406
pmcid: 5078823
Gentileschi S, Servillo M, Garganese G, Fragomeni S, De Bonis F, Cina A et al (2017) The lymphatic superficial circumflex iliac vessels deep branch perforator flap: a new preventive approach to lower limb lymphedema after groin dissection-preliminary evidence. Microsurgery 37(6):564–573
doi: 10.1002/micr.30142
pubmed: 27987230
Hirakawa S, Detmar M, Kerjaschki D, Nagamatsu S, Matsuo K, Tanemura A et al (2009) Nodal lymphangiogenesis and metastasis: role of tumor-induced lymphatic vessel activation in extramammary Paget’s disease. Am J Pathol 175(5):2235–2248
doi: 10.2353/ajpath.2009.090420
pubmed: 19815713
pmcid: 2774085
Hummel M, Edelmann D, Kopp-Schneider A (2017) Clustering of samples and variables with mixed-type data. PLoS One [Internet] 12(11). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705083/
Inoguchi N, Matsumura Y, Kanazawa N, Morita K, Tachibana T, Sakurai T et al (2007) Expression of prostate-specific antigen and androgen receptor in extramammary Paget’s disease and carcinoma. Clin Exp Dermatol 32(1):91–94
pubmed: 17163959
Kang Z, Xu F, Zhu Y, Fu P, Zhang Q-A, Hu T et al (2016) Genetic analysis of mismatch repair genes alterations in extramammary Paget disease. Am J Surg Pathol 40(11):1517–1525
doi: 10.1097/PAS.0000000000000709
pubmed: 27487738
Karam A, Berek JS, Stenson A, Rao J, Dorigo O (2008) HER-2/neu targeting for recurrent vulvar Paget’s disease. A case report and literature review. Gynecol Oncol 111(3):568–571
doi: 10.1016/j.ygyno.2007.12.014
pubmed: 18252264
Larbouret C, Gaborit N, Chardès T, Coelho M, Campigna E, Bascoul-Mollevi C et al (2012) In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors’ down-regulation and dimers’ disruption. Neoplasia 14(2):121–130
doi: 10.1593/neo.111602
pubmed: 22431920
pmcid: 3306257
Liegl B, Horn L-C, Moinfar F (2005) Androgen receptors are frequently expressed in mammary and extramammary Paget’s disease. Mod Pathol Off J U S Can Acad Pathol Inc 18(10):1283–1288
Mantovani G, Fagotti A, Franchi M, Scambia G, Garganese G (2019) Reviewing vulvar Paget’s disease molecular bases. Looking forward to personalized target therapies: a matter of CHANGE. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc 29:422–429
doi: 10.1136/ijgc-2018-000080
Tagliaferri L, Casà C, Macchia G, Pesce A, Garganese G, Gui B et al (2018) The role of radiotherapy in extramammary Paget disease: a systematic review. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc 28(4):829–839
doi: 10.1097/IGC.0000000000001237
Teng MWL, Ngiow SF, Ribas A, Smyth MJ (2015) Classifying cancers based on T cell Infiltration and PD-L1. Cancer Res 75(11):2139–2145
doi: 10.1158/0008-5472.CAN-15-0255
pubmed: 25977340
pmcid: 4452411
van der Linden M, Meeuwis KAP, Bulten J, Bosse T, van Poelgeest MIE, de Hullu JA (2016) Paget disease of the vulva. Crit Rev Oncol Hematol 101:60–70
doi: 10.1016/j.critrevonc.2016.03.008
pubmed: 26971063
Van der Zee AGJ, Oonk MH, De Hullu JA, Ansink AC, Vergote I, Verheijen RH et al (2008) Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol Off J Am Soc Clin Oncol. 26(6):884–889
doi: 10.1200/JCO.2007.14.0566
Wilkinson EJ, Brown HM (2002) Vulvar Paget disease of urothelial origin: a report of three cases and a proposed classification of vulvar Paget disease. Hum Pathol 33(5):549–554
doi: 10.1053/hupa.2002.124788
pubmed: 12094382
Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: american Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol Off J Am Soc Clin Oncol 31(31):3997–4013
doi: 10.1200/JCO.2013.50.9984
Xu X, Shao N, Qiao D, Wang Z, Song N, Song N (2015) Expression of vascular endothelial growth factor and basic fibroblast growth factor in extramammary Paget disease. Int J Clin Exp Pathol 8(3):3062–3068
pubmed: 26045818
pmcid: 4440127
Zhang C, Zhang P, Sung CJ, Lawrence WD (2003) Overexpression of p53 is correlated with stromal invasion in extramammary Paget’s disease of the vulva. Hum Pathol 34(9):880–885
doi: 10.1016/S0046-8177(03)00289-2
pubmed: 14562283
Zhou S, Zhong W, Mai R, Zhang G (2017) Mammary and extramammary Paget’s disease presented different expression pattern of steroid hormone receptors. Biomed Res Int 2017:3768247
pubmed: 29082243
pmcid: 5610822